Ratings Iconovo AB

Equities

ICO

SE0010868943

Market Closed - Nasdaq Stockholm 11:10:10 2024-05-10 EDT 5-day change 1st Jan Change
7.84 SEK -1.51% Intraday chart for Iconovo AB -2.00% -32.12%

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
-32.12% 11.52M -
+9.48% 27.43B
B+
-28.65% 3.18B
B-
-16.08% 2.53B
C+
+19.05% 2.49B -
A-
+11.11% 2.16B
B
-4.24% 2.03B -
+1.69% 1.31B -
+29.73% 1.29B
C
+8.01% 1.17B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW